Clinical trials: Rivaroxaban
Venous Thromboembolism
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Rationale: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE) or deep venous thrombosis (DVT) potentially resulting in a fatal pulmonary embolism (PE).
- Trial name
- DARINA (NCT01431456)
- Testing
- Dabigatran, Rivaroxaban, Nadroparin
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Martini Hospital Groningen
Cervical Artery Dissection
Antithrombotic Treatment Strategies in Cervical Artery Dissection
The goal of this clinical randomised controlled trial is to compare two treatment strategies - antiplatelet treatment strategy versus anticoagulation treatment strategy - in patients with acute, ischemic Cervical Artery…
- Trial name
- TREAT-CAD 2 (NCT07639892)
- Testing
- Antiplatelet Treatment Strategy, Anticoagulation Treatment Strategy
- Volunteers
- 1,100 people
- Sponsor
- University Department of Geriatric Medicine FELIX PLATTER
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Deep Vein Thrombosis
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis
The treatment of isolated distal deep vein thrombosis remains one of the most debated issues in the field of venous thromboembolism and only very few studies have directly addressed the issue of treatment in objectively confirmed…
- Trial name
- RIDTS (NCT02722447)
- Testing
- rivaroxaban
- Where
- 7 sites in Italy
- Volunteers
- 1,100 people
- Sponsor
- Walter Ageno
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Atrial Fibrillation
Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
The purpose of this study is to evaluate the antiinflammatory effects of rivaroxaban compared with dabigatran in patients with atrial fibrillation.
- Trial name
- RIVAL-AF (NCT02331602)
- Testing
- Rivaroxaban, Dabigatran
- Where
- 16 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Atrial Fibrillation, Intracerebral Hemorrhage
PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
Atrial fibrillation (AF) is the most common form of irregular heart rhythm. In people with AF, blood clots often form in the heart, which can travel to the brain.
- Trial name
- PRESTIGE-AF (NCT03996772)
- Testing
- Apixaban Oral Tablet, Dabigatran, Edoxaban Tablets
- Where
- 64 sites in Austria, France and 4 more
- Volunteers
- 319 people
- Sponsor
- Imperial College London
Chronic Kidney Diseases, Dialysis-dependent Kidney Failure
Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease
The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector, outcomes assessor), placebo-controlled trial.
- Conditions
- Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease
- Trial name
- TRACK (NCT03969953)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- 88 sites in Australia, Belgium and 10 more
- Volunteers
- 1,753 people
- Sponsor
- The George Institute
Deep Venous Thromboses, Laparotomy Patients
Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults.
- Trial name
- NCT07243080
- Testing
- rivaroxaban (10mg), Enoxaparin 40 mg SC
- Where
- Pakistan
- Volunteers
- 212 people
- Sponsor
- Mayo Hospital Lahore
Myeloproliferative Neoplasm
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs) may have improved bleeding…
- Trial name
- MPN-DOACs (NCT04192916)
- Testing
- DOACs
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 442 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Osteoarthritis, Hip, Femur Head Necrosis
Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
This prospective study compares an oral direct factor Xa inhibitor with LMWH for thromboprophylaxis in the patients undergoing THA.
- Conditions
- Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures
- Trial name
- NCT02379663
- Testing
- Rivaroxaban, Enoxaparin, Normal saline
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Atrial Fibrillation, Venous Thromboembolism
Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm
This study shall determine whether XAPPORT - a mobile device app based on different guidelines, the summary of product characteristics of rivaroxaban, and clinical facts and practice - provides adequate guidance to physicians…
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- VeriXAPPORT (NCT02900404)
- Testing
- XAPPORT, Expert Panel ("gold standard")
- Sponsor
- Bayer
Coronary Artery Disease, Saphenous Vein Graft Patency
Surgical Revascularization Outcomes After Oral Anticoagulation or Antiplatelets
The primary purpose of this study is to evaluate whether treatment with oral anticoagulation or oral anticoagulation and aspirin is better than aspirin alone in cardiovascular outcomes and saphenous graft patency in patients…
- Trial name
- SCOOP (NCT03605433)
- Testing
- Rivaroxaban
- Where
- Portugal
- Volunteers
- 100 people
- Sponsor
- Unidade Local de Saúde de Coimbra, EPE
Covid19
Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in…
- Trial name
- XACT (NCT04640181)
- Testing
- Enoxaparin, Rivaroxaban
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- St. David's HealthCare
Deep Vein Thrombosis, Post Thrombotic Syndrome
Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
The TILE pilot study will be a multicenter, open-label, assessor-blinded RCT (randomized control trial) comparing extended LMWH (Low Molecular Weight Heparin) vs.
- Trial name
- TILE (NCT04794569)
- Testing
- tinzaparin, Rivaroxaban
- Where
- 5 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Sunnybrook Health Sciences Centre
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Hip Osteoarthritis, Blood Loss
Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.
The purpose of this study is to determine which of the following drugs: enoxaparin, dabigatran and rivaroxaban causes least blood loss after total hip replacement (THR).
- Trial name
- NCT02085824
- Testing
- Enoxaparin, rivaroxaban, dabigatran
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Centre of Postgraduate Medical Education
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Venous Thrombosis, Deep, Arthroplasty Complications
Selective Thromboembolism Prophylaxis After Arthroplasty
Asian populations have a lower rate of high-risk gene mutations of venous thrombosis, which means a reasonable perioperative anticoagulant management after hip or knee arthroplasty for Caucasian populations may be too excessive…
- Trial name
- NCT03804697
- Testing
- selective anticoagulation
- Volunteers
- 197 people
- Sponsor
- Guangdong Provincial People's Hospital